Merck said Wednesday it would pay $10 billion to buy the biotech Verona Pharma, which sells a new lung-disease drug that ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

The list recommending customs duty of 5% includes 74 drugs, while another suggesting full exemption has 69 drugs. A separate ...

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

Pharmaceutical giant Merck & Co. (MRK) is buying British lung therapy firm Verona Pharma (VRNA) for $10 billion U.S. In a written statement, Merck said the deal will strengthen its respiratory ...